MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3389/fimmu.2025.1610136

Медицинская библиотека · Frontiers in immunology · 2025

Impact of telitacicept on gonadal function in adult female patients with systemic lupus erythematosus: a prospective cohort study.

Zhang Ziyan, Zeng Qianni, Wen Yabin, Zhou Yuqing, Zhang Lihua

СтатьяПеревод в очереди

Аннотация

BACKGROUND/AIM: Telitacicept has shown promise in disease control of systemic lupus erythematosus (SLE). This study aimed to evaluate the impact of telitacicept on gonadal function in adult female patients with SLE.

METHODS

In this prospective cohort study, adult female SLE patients aged 18 to 45 years were included and divided into telitacicept and non-telitacicept group. Hormonal levels of estradiol (E2), follicle-stimulating hormone (FSH), luteinizing hormone (LH), prolactin (PRL), and anti-Müllerian hormone (AMH) were measured at baseline, month 1, 3, and 6 post-treatment. Generalized estimating equations adjusting for baseline confounders was used.

RESULTS

A total of 78 patients were included, with 38 in the telitacicept group and 40 in the non-telitacicept group. Telitacicept significantly decreased PRL and LH levels (both adjusted Ptime<0.001), with greater reduction compared to non-telitacicept treatment (adjusted Pgroup=0.001 and <0.001, respectively). In the multivariate logistic regression, telitacicept treatment was associated with a significantly lower incidence of abnormal PRL levels at month 6 (odds ratio=0.138, 95% confidence interval: 0.036-0.527, P = 0.004). The levels of AMH and E2 were increased and the levels of FSH were decreased (all adjusted Ptime<0.05), while the changes of AMH, E2 and FSH levels were similar between the two groups (all adjusted Pgroup>0.05). SLE Disease Activity Index scores were significantly lower with telitacicept compared to non-telitacicept treatment at month 1, 3 and 6 post-treatment (all P<0.05). The incidence of adverse events was similar between the two groups.

CONCLUSION

Telitacicept demonstrates significant benefits in improving gonadal function and controlling disease activity in female SLE patients.

Для цитирования: Zhang Ziyan, Zeng Qianni, Wen Yabin, Zhou Yuqing, Zhang Lihua. Impact of telitacicept on gonadal function in adult female patients with systemic lupus erythematosus: a prospective cohort study.. Frontiers in immunology. 2025. DOI: 10.3389/fimmu.2025.1610136.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.